AI spending isn’t expected to slow in 2026. In a research note shared with TheStreet, Goldman Sachs predicted that ...

US President Donald Trump announced on Friday that nine drugmakers have agreed to lower the cost of their prescription drugs ...

The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models.

U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S.

Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi have agreed to drug pricing deals.

Nine large pharma companies have reached agreements with the Trump administration to lower certain drug prices in the U.S. | ...

The companies were the latest to agree to sell drugs to Medicaid and directly to consumers at discounted prices. President ...

President Trump told NBC News that he hasn't ruled out war against Venezuela. “I don’t rule it out, no,” Trump told the news ...

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many other drugmakers are hot on its tail, Lilly has consistently demonstrated that, ...

Three stocks that did well during the last big bear market in 2022 are AbbVie ( ABBV +0.15%), Eli Lilly ( LLY +2.09%), and Chevron ( CVX 1.32%). Here's why they could potentially be good investments ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...